Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Importance: Antidepressants are one of the most commonly prescribed classes of psychotropic medications among US youths. For adults, there is emerging evidence on the increased risk of type 2 diabetes in association with antidepressant use. However, little is known about the antidepressant treatment-emergent risk of type 2 diabetes among youths. Objective: To assess the association between antidepressant use and the risk of incident type 2 diabetes in youths by antidepressant subclass and according to duration of use, cumulative dose, and average daily dose. Design, Setting, and Participants: A retrospective cohort study was conducted using Medicaid claims data from 4 geographically diverse, large states of youths 5 to 20 years of age who initiated antidepressant treatment from January 1, 2005, to December 31, 2009. Exposures: Antidepressant use (selective serotonin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic or other cyclic antidepressants, and other antidepressants) was assessed using the following 4 time-varying measures: current or former use, duration of use, cumulative dose, and average daily dose. Main Outcomes and Measures: Incident type 2 diabetes was assessed using discrete-time failure models, adjusting for disease risk score estimated using more than 125 baseline and time-dependent covariates. Results: In this cohort of 119 608 youths aged 5 to 20 years who initiated antidepressant treatment (59 087 female youths and 60 521 male youths; 54.7% between 5 and 14 years of age) with a mean follow-up of 22.8 months, 79 285 [66.3%] had SSRI or SNRI exposure. The risk of type 2 diabetes was significantly greater during current use than former use of SSRIs or SNRIs (absolute risk, 1.29 per 10 000 person-months vs 0.64 per 10 000 person-months; adjusted relative risk [RR], 1.88; 95% CI, 1.34-2.64) and tricyclic or other cyclic antidepressants (absolute risk, 0.89 per 10 000 person-months vs 0.48 per 10 000 person-months; RR, 2.15; 95% CI, 1.06-4.36), but not of other antidepressants (absolute risk, 1.15 per 10 000 person-months vs 1.12 per 10 000 person-months; RR, 0.99; 95% CI, 0.66-1.50). Furthermore, for youths currently using SSRIs or SNRIs, the risk of type 2 diabetes increased with the duration of use (RR, 2.66; 95% CI, 1.45-4.88 for >210 days and RR, 2.56; 95% CI, 1.29-5.08 for 151-210 days compared with 1-90 days) and with the cumulative dose (RR, 2.44; 95% CI, 1.35-4.43 for >4500 mg and RR, 2.17; 95% CI, 1.07-4.40 for 3001-4500 mg compared with 1-1500 mg in fluoxetine hydrochloride dose equivalents). By contrast, neither the duration nor the cumulative dose of other antidepressants was associated with an increased risk of type 2 diabetes. The risk of type 2 diabetes increased significantly with the average daily dose among youths with more than 150 days of SSRI or SNRI use (RR, 2.39; 95% CI, 1.04-5.52 for >15.0 vs ≤15.0 mg/d) but not among youths with 1 to 150 days of SSRI or SNRI use. Conclusions and Relevance: In a large cohort of youths insured by Medicaid, the use of SSRIs or SNRIs-the most commonly used antidepressant subclass-was associated with an increased risk of type 2 diabetes that intensified with increasing duration of use, cumulative dose, and average daily dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
D'Agostino, R. B., Lee, M., Belanger, A. J., Cupples, L. A., Anderson, K., & Kannel, W. B. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091214 · Cited by 798
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730
Trends in Mental Health Care among Children and Adolescents
Olfson, M., Druss, B. G., & Marcus, S. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1413512 · Cited by 408
Hayasaka, Y., Purgato, M., Magni, L. R., Ogawa, Y., Takeshima, N., Cipriani, A., Barbui, C., Leucht, S., & Furukawa, T. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.021 · Cited by 401 · cited 3×
“We conductedananalysisofolderyouths(10-20yearsofage)wherein antidepressant usewasmost prevalent.(1,17) In another analysis, wedidnotrequirethe90-daytimewindowtoaccountforthecarryovereffects.”
BackgroundDepression as a Risk Factor for Diabetes: A Meta-Analysis of Longitudinal Studies
Rotella, F., & Mannucci, E. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07922 · Cited by 360
Rubin, R. R., Ma, Y., Marrero, D. G., Peyrot, M., Barrett-Connor, E. L., Kahn, S. E., Haffner, S. M., Price, D. W., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2008) · Diabetes Care · doi:10.2337/dc07-1827 · Cited by 242
An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use
Blumenthal, S. R., Castro, V. M., Clements, C. C., Rosenfield, H. R., Murphy, S. N., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.414 · Cited by 151
Arbogast, P. G., & Ray, W. A. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr143 · Cited by 138
Rubin, R. R., Ma, Y., Peyrot, M., Marrero, D. G., Price, D. W., Barrett-Connor, E., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2010) · Diabetes Care · doi:10.2337/dc10-1033 · Cited by 71
Cited by
Jin, M., Lu, J., Chen, Z., Nguyen, S. H., Mao, L., Li, J., Yuan, Z., & Guo, J. (2018) · Environment International · doi:10.1016/j.envint.2018.07.046 · Cited by 182
Robinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Imaizumi, T., Toda, T., Maekawa, M., Sakurai, D., Hagiwara, Y., Yoshida, Y., Ando, M., & Maruyama, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-22048-9 · Cited by 12
Metadata
- Authors
- Burcu, M., Zito, J. M., Safer, D. J., Magder, L. S., dosReis, S., Shaya, F. T., & Rosenthal, G. L.
- Venue
- JAMA Pediatrics
- Publisher
- American Medical Association (AMA)
- Published
- 2017-12-01
- Volume
- 171
- Issue
- 12
- Pages
- 1200
- ISSN
- 1072-4710 (ISSN-L)
- 2168-6203
- OpenAlex
- W2766402528
- Cited by
- 52
- References
- 11
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.